常态血性原发性甲状腺功能增强症与心脏代谢变化无关
Marco Barale1, Federica Maiorino2, Alessia Pusterla2
1Division of Oncological Endocrinology; Department of Medical Sciences, University of Turin, Turin, Italy. marco.barale@unito.it.
常态血性原发性甲状腺功能过高症 (NC-PHPT) 没有表现出心脏代谢变化. 高热血性原发性甲状腺功能障碍症 (HC-PHPT) 与心血管风险增加有关,这表明高热血症驱动这些并发症.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 心血管健康 心血管健康
背景情况:
- 心脏代谢障碍是已知的高热血性原发性甲状腺功能障碍症 (HC-PHPT) 的并发症.
- 心脏代谢风险和常态血性原发性副甲状腺症 (NC-PHPT) 之间的关联尚未得到充分证实.
- 了解这些关联对于全面的患者管理至关重要.
研究的目的:
- 调查HC-PHPT和NC-PHPT中的心脏代谢变化.
- 确定HC-PHPT中发现的心脏代谢风险是否也存在于NC-PHPT中.
- 探索疾病活动指数与心脏代谢变化之间的关系.
主要方法:
- 进行了一项病例控制研究,将HC-PHPT (n=17) 和NC-PHPT (n=17) 的患者与对照组 (n=34) 的患者进行比较.
- 参与者根据年龄,性别和BMI进行了匹配.
- 评估包括葡萄糖水平,脂质概况,血压和心血管事件史.
主要成果:
- 与对照组相比,NC-PHPT患者在葡萄糖,脂质水平,血压或相关疾病的频率上没有显著差异.
- 与对照组相比,HC-PHPT患者的葡萄糖和脂质变化,高血压和心血管事件的患病率显著更高.
- 在HC-PHPT中较高的水平与葡萄糖和静脉血压升高有显著的相关性.
结论:
- 常态热血性原发性甲状腺功能过高症 (NC-PHPT) 与心脏代谢变化无关.
- 过血症似乎在原发性甲状腺功能障碍症中的心脏代谢障碍的发展中起着主导作用.
- 这些发现强调了水平在PHPT相关并发症中的重要性.
更多相关视频
07:13Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation
Published on: March 14, 2017
07:12Establishment of a Simple and Effective Rat Model for Intraoperative Parathyroid Gland Imaging
Published on: August 17, 2022
相关概念视频
Skeleton and Calcium Homeostasis
The Parathyroid Glands
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by...
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Synthesis and Functions of Calcitonin
The exact mechanisms by which calcitonin operates in calcium homeostasis remain elusive, but its significance is evident in several vital...
Chronic Kidney Disease II: Clinical Manifestations
Cardiomyopathy III: Hypertrophic Cardiomyopathy
